<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03587558</url>
  </required_header>
  <id_info>
    <org_study_id>2017-07-022</org_study_id>
    <nct_id>NCT03587558</nct_id>
  </id_info>
  <brief_title>Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract</brief_title>
  <acronym>FOREVER</acronym>
  <official_title>Effects of Carvedilol on Suppressing the Premature Ventricular Complex/Ventricular Tachycardia From Outflow Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keimyung University Dongsan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chong Kun Dang Pharmaceutical Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Keimyung University Dongsan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carvedilol is known to be effective in reducing ventricular arrhythmias and mortality in
      patients with heart failure. It is suggested that one of the mechanisms is its ability to
      block store overload-induced Calcium release which activates spontaneous calcium release by
      Ryanodine receptors. Ventricular outflow tract tachyarrhythmia is known to be associated with
      calcium overload due to activation of Ryanodine receptors. The aim of this study is to
      evaluate the efficacy of Carvedilol on premature ventricular complex(PVC)/ventricular
      tachycardia(VT) originating from outflow tract.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Carvedilol is one of the third-generation beta-blockers effective in reducing ventricular
      arrhythmias and mortality in patients with heart failure. Antioxidative and alpha - blocking
      effects, along with nonselective beta - blockade, have been described as a mechanism of
      effect in various diseases.

      The antiarrhythmic effect of carvedilol inhibiting atrial fibrillation or ventricular
      arrhythmia has been reported, but its mechanism is not yet clear. Among them, inhibition of
      store overload-induced Ca2+ release (SOICR) is suggested as an antiarrhythmic mechanism of
      carvedilol.

      Stimulation of the beta receptor leads to the entry of calcium into the sarcoplasmic
      reticulum (SR) by opening the L-type calcium channel. The influx of calcium through the
      L-type calcium channel also increases the calcium release through the Ryanodine receptor
      (RyR) in the sarcoplasmic reticulum. This is called Ca-induced Ca release and is known as a
      normal physiological response. However, when calcium overload in the myofibrillar body
      occurs, spontaneous calcium release, known as SOICR, can occur through RyR, which can make
      triggered activity by inducing Na+/Ca2+ exchanger present in myocardium, leading to severe
      arrhythmia. Among several beta-blockers, only carvedilol has been known as a drug that can
      directly inhibit SOICR in combination with beta-blockade effect.

      Ventricular tachyarrhythmia originating from the ventricular outflow tract is an arrhythmia
      occurring in a patient with normal cardiac function. The mechanism of the arrhythmia is known
      to be triggered activity which is caused by activation of RyR due to increased cyclic
      adenosine monophasphate, resulting in calcium overload, eventually causing activation of
      Na+/Ca2+ exchanger. The aim of this study is to evaluate the efficacy of Carvedilol on PVC/VT
      originating from outflow tract.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PVC burden</measure>
    <time_frame>3 months after reaching the maximum tolerated dose</time_frame>
    <description>Percentage of PVC/VT beat out of 24 hour total heart beat in Holter monitoring</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom assessment scale</measure>
    <time_frame>3 months after reaching the maximum tolerated dose</time_frame>
    <description>questionnaire for PVC/VT symptoms using symptom assessment scale (Min 0 to Max 100)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effect of drugs</measure>
    <time_frame>3 months after reaching the maximum tolerated dose</time_frame>
    <description>Difference in occurrence of side effects of each drug</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">104</enrollment>
  <condition>Ventricular Premature Complexes</condition>
  <condition>Outflow Tract</condition>
  <condition>Carvedilol</condition>
  <arm_group>
    <arm_group_label>Carvedilol group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT. Dilatrend® sustained release form of Chong Kun Dang Pharmaceutical will be used (initial dose: 8 mg sustained release form). Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flecainide group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group are taking flecainide to inhibit outflow tract PVC/VT. Tambocor® of JW Pharmaceutical will be used. Outpatient follow-up will be performed every 2 weeks and the dose is increased from the initial dose to a maximal tolerable dose, at the discretion of the investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Patients in this group are taking carvedilol to inhibit outflow tract PVC/VT.</description>
    <arm_group_label>Carvedilol group</arm_group_label>
    <other_name>Dilatrend</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flecainide</intervention_name>
    <description>Patients in this group are taking flecainide to inhibit outflow tract PVC/VT.</description>
    <arm_group_label>Flecainide group</arm_group_label>
    <other_name>Tambocor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ventricular premature complexes/ventricular tachycardias originating
             from ventricular outflow tract confirmed on the 12-lead surface ECG

          -  Patients with PVC burden of 5% or more in 24-hour Holter monitoring

          -  Patients with normal left ventricular function

               -  left ventricular ejection fraction ≥50%

          -  Patients without structural heart disease

        Exclusion Criteria:

          -  Pregnant, trying to become pregnant or breast feeding

          -  History of bronchial asthma

          -  History of coronary arterial disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seongwook Han, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Keimyung University Dongsan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jongmin Hwang, M.D., Ph.D.</last_name>
    <phone>+82-53-250-7333</phone>
    <email>dsmcep@dsmc.or.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jongmin Hwang, M.D.</last_name>
      <phone>+82-53-250-7333</phone>
      <email>dsmcep@dsmc.or.kr</email>
    </contact>
    <investigator>
      <last_name>Seongwook Han, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoon-Nyun Kim, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hyoung-Seob Park, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jongmin Hwang, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung Hwan Bae, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>42415</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Gu Shin, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, Department of Internal Medicine, Daegu Catholic University Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42472</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Soo Lee, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyung Wook Park, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong-Il Choi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eue-Keun Choi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Cardiovascular Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boyoung Joung, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Kim, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Keun On, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung-Hwan Kim</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>July 2, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2018</study_first_posted>
  <last_update_submitted>July 16, 2018</last_update_submitted>
  <last_update_submitted_qc>July 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>carvedilol</keyword>
  <keyword>SOICR</keyword>
  <keyword>triggered activity</keyword>
  <keyword>outflow tract PVC/VT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Premature Birth</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Premature Complexes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flecainide</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual participant data for all primary and secondary outcome measures will be made available.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available within 6 months of study completion.</ipd_time_frame>
    <ipd_access_criteria>Data access requests will be reviewed by an external independent Review Panel. Requestors will be required to sign a Data Access Agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

